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ABSTRACT
Given the importance of appropriate diagnosis and appropriate assessment of cutaneous symptoms in treat-
ment of atopic dermatitis, the basics of treatment in this guideline are composed of (1) investigation and coun-
termeasures of causes and exacerbating factors, (2) correction of skin dysfunctions (skin care), and (3) phar-
macotherapy, as three mainstays. These are based on the disease concept that atopic dermatitis is a inflam-
matory cutaneous disease with eczema by atopic diathesis, multi-factorial in onset and aggravation, and ac-
companied by skin dysfunctions. These three points are equally important and should be appropriately com-
bined in accordance with the symptoms of each patient. In treatment, it is important to transmit the etiological,
pathological, physiological, or therapeutic information to the patient to build a favorable partnership with the pa-
tient or hisher family so that they may fully understand the treatment. This guideline discusses chiefly the ba-
sic therapy in relation to the treatment of this disease. The goal of treatment is to enable patients to lead an un-
interrupted social life and to control their cutaneous symptoms so that their quality of life (QOL) may meet a sat-
isfactory level.
The basics of treatment discussed in this guideline are based on the “Guidelines for the Treatment of Atopic
Dermatitis 2008” prepared by the Health and Labour Sciences Research and the “Guidelines for the Manage-
ment of Atopic Dermatitis 2009 (ADGL2009)” prepared by the Atopic Dermatitis Guidelines Advisory Commit-
tee, Japanese Society of Allergology in principle.
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1. DEFINITIONDISEASE CONCEPT, PATHO-
PHYSIOLOGYETIOLOGY OF ATOPIC DER-
MATITIS
1.1. DEFINITION AND DISEASE CONCEPT
The guidelines adopt the definition (concept)1 of the
Japanese Dermatological Association on atopic der-
matitis that states “atopic dermatitis is a disease with
repeated exacerbation and remission, chiefly charac-
terized by eczema with itch, mostly exhibited by pa-
tients with atopic diathesis.”
1.2. PATHOPHYSIOLOGY
1.2.1. Inflammatory Mechanism
Atopic dermatitis is a disease included in the ec-
zemadermatitis group. The dominant mechanisms
of atopic dermatitis in lesional skin are governed by
Th2 cell-related cytokines such as IL-4 and IL-13, and
chemokines such as TARC and eotaxin.2 This is, how-
ever, a pathology in the acute stage, and Th1 cells
producing IFN-γ and IL-12 are reportedly dominant in
the chronic stage.3 Langerhans cells and mast cells
are involved in the inflammatory response by ex-
pressing a high affinity IgE receptor (FcεRI) that
causes antigen presenting cells and mast cells to re-
lease histamine, cytokines, etc. In an eczematous le-
sion of atopic dermatitis, antimicrobial peptides (de-
fensins, cathelicidins, etc.) are inhibited from being
expressed by keratinocytes.4
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Fig.　1　Causes and exacerbating factors. Since causes and exacerbating factors vary among patients, care 
should be taken to identify them sufficiently for each patient before taking removal measures. Modifi ed from refer-
ence 15.
Reference
Note
Abnormal skin functions seen in atopic dermatitis
Atopic dermatitis should be treated based on a good understanding of abnormal skin functions.
●Decreased water retentivity/barrier functions ●Lowered itch threshold ●Susceptibility to infection
Younger than 
2 years old
2-12 years old
13 years and 
older to adult
○Foods (egg, cow’s milk, wheat, 
etc.) 
○sweat ○drying ○scratching
○physicochemical irritation 
(slaver, soap, detergent, 
rubbing of clothes, etc.) 
○mites, dust, pets, etc.
○microbes/fungi etc.
○sweat ○drying ○scratching
○physicochemical irritation 
(soap, detergent, rubbing of 
clothes, etc.) 
○microbes/fungi
○mites, dust, pets, etc.
○stress
○foods (egg, cow’s milk, wheat, 
etc.)  etc.
1.2.2. Skin Dysfunctions
Expression of ceramide5 and filaggrin6 decreases in
skin with atopic dermatitis, particularly in lesions,
and is considered as a primary cause of barrier dys-
functions. It is also considered as a secondary phe-
nomenon associated with inflammation and as a
cause of atopic dermatitis. Atopic dermatitis is accom-
panied by an acute itch allegedly due to a lowered
threshold of itch. Involvement of IL-31 has been re-
ported as a cause of the above.7
1.3. ETIOLOGY
Atopic dermatitis is caused by combination of genetic
and environmental factors.
1.3.1. Genetic Factors
Most patients have a history or personal history of an
atopic disease. The onset of the diathesis and the dis-
ease tends to be inherited from parents. Genetic fac-
tors reported to date include mutation of the -590CT
in the IL-4 gene promoter region, the IL-4Rα subunit
gene, the IL-13 gene, and a gene abnormality of filag-
grin, a component of the horny cell layer.
1.3.2. Etiological and Exacerbating Factors
A wide variety of etiological and exacerbating factors
has been proposed, with the importance level of each
varying among individual patients. In addition, inflam-
mation associated with this disease will be elucidated
by both allergic and non-allergic mechanisms. Eti-
ological and exacerbating factors vary among age
groups. While the dominant factors in the first half of
childhood include foods, sweating, physical irritation
(including scratching), environmental factors, mi-
crobesfungi, the dominant factors in the second half
of childhood to adulthood include environmental fac-
tors, sweating, physical irritation (including scratch-
ing), microbesfungi, contact allergens, stress, and
foods (Fig. 1).
2. EPIDEMIOLOGY OF ATOPIC DERMATITIS
2.1. GLOBAL PREVALENCE OF ATOPIC DER-
MATITIS AND ITS CHANGES
An epidemiological survey (Phase I) was conducted
from 1994 to 1996 by the International Study of
Asthma and Allergies in Childhood (ISAAC).8 The
Atopic Dermatitis
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Fig.　2　Prevalence of atopic dermatitis by age groups in the fi scal year of 1996-2008. 4 months old from: Hok-
kaido, Kanto, Chubu, Kinki, Chugoku, Shikoku, and Kyushu (seven districts, n = 2744). Children with 1.5 years 
old, 3 years old , 1st grade of elementary, 6th grade of elementary from: Hokkaido, Tohoku, Kanto, Chubu, Kinki, 
Chugoku, Shikoku, and Kyushu (eight districts, n = 6424). University students from: University of Tokyo, Kinki 
University, Hiroshima University (n = 8317). Adult (20s to 60s) from: Personnel of University of Tokyo and Kinki 
University (n = 2943). Adapted from reference 15.
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global prevalence in 6-7 year olds ranged from 1.1% in
Iran to 18.4% in Sweden and was 7.3% on average. The
global prevalence in 13-14 year olds ranged from 0.8%
in Albania to 17.7% in Nigeria and was 7.4% on aver-
age. The highest prevalence was seen mostly in in-
dustrial nations including Sweden, Finland, UK, Ja-
pan, Australia, and New Zealand. In the epidemiologi-
cal survey (Phase II) conducted from 2001 to 2003 by
the ISAAC, few nations showed a significant decrease
in the prevalence in 6-7 year olds compared with their
prevalence reported in Phase I of the survey.9 In
terms of the age group of 13-14 year olds, some of the
advanced nations with a high prevalence reported in
Phase I (UK, New Zealand etc.) showed a decrease in
Phase II.
2.2. EPIDEMIOLOGICAL SURVEY IN JAPAN
A nationwide prevalence survey was conducted in Ja-
pan from 2000 to 2008 using the medical examination
data from public health centers, elementary schools,
and universities. Figure 2 shows the prevalence by
age groups. In addition, a prevalence survey on the
adult atopic dermatitis was performed using the
medical examination for 2,943 personnel of 2 univer-
sities10 (Fig. 2). Figure 3 shows the ratios of patients
with atopic dermatitis analyzed by severity for age
groups from 1.5 years to university-aged students and
from the 20s to the 60s.10 The data on occurrence and
progression of infantile atopic dermatitis is provided
by a report based on a follow-up study of infants of 4
months to 3 years old performed in the Health and
Labour Sciences Research, from 2006 to 2008, in Yok-
ohama City, Chiba City, and Fukuoka City. The re-
port shows that 16.2% of ordinary infants, who re-
ceived a medical examination at 4 months of age, de-
veloped atopic dermatitis. Atopic dermatitis remitted
in 50% of the 4-month-old patients before the age of 18
months, indicating an extremely dynamic change in
progression of atopic dermatitis in infancy.11 This sur-
vey showed a cumulative incidence rate before 3
years of age of a little more than 30%, similar to re-
ports from overseas.
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Fig.　3　Ratios of patients with atopic dermatitis by severities in the fi scal year of 2000-2008. The severity criteria 
are based on the “Severity Index” in the “Guidelines for the Treatment of Atopic Dermatitis 2008” prepared by the 
Health and Labour Sciences Research, Ministry of Health and Welfare, Japan. Modifi ed from reference 15.
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3. DIAGNOSIS OF ATOPIC DERMATITIS
3.1. DIAGNOSTIC CRITERIA FOR ATOPIC DER-
MATITIS
(1) Diagnostic criteria proposed by Hanifin and Ra-
jka: The diagnostic criteria of Hanifin and Rajka are
internationally most popular.
(2) Diagnostic criteria proposed by the Japanese
Dermatological Association: The Japanese Derma-
tological Association developed diagnostic criteria in
1994, which was partly revised in 2008 (Table 1). Us-
ing these criteria, all diseases that meet the 3 require-
ments of itch, characteristic rashes and distribution,
and chronicrecurrent progression, will be diagnosed
as atopic dermatitis irrespective of the severity of
symptoms.1
(3) Diagnostic criteria under the Studies on Psy-
chosomatic Disorder by Ministry of Health and Wel-
fare: These criteria are limited to atopic dermatitis in
infancy through childhood. Separate diagnostic crite-
ria are established for infants, young children, and
schoolchildren.
This guideline employs the diagnostic criteria of
the Japanese Dermatological Association or the Study
on Psychosomatic Disorder by Ministry of Health
and Welfare. Those two criteria are consistent in prin-
ciple.12
3.2. LABORATORY DATA USED AS A REFER-
ENCE FOR DIAGNOSIS
(1) Serum total IgE level: A high serum total IgE
level is observed in approximately 80% of patients
with atopic dermatitis. It is also reportedly signifi-
cantly correlated with the severity (the later dis-
cussed SCORing Atopic Dermatitis [SCORAD] sever-
ity index).
(2) Blood eosinophil count: Eosinophilia is seen in
blood and the rash tissue of many but not all patients.
Because it changes more rapidly than IgE, it serves
as an index to assess changes of the disease condi-
tion.
(3) Specific IgE antibody titer: Patients with atopic
dermatitis are apt to produce IgE antibodies in re-
sponse to various allergens such as mites, foods, and
Atopic Dermatitis
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Table　1　Defi nition and diagnostic criteria for atopic dermatitis by the Japanese Dermatological Association
Defi nition
Atopic dermatitis is a pruritic, eczematous dermatitis; its symptoms chronically fl uctuate with remissions and relapses.
Most individuals with atopic dermatitis have atopic diathesis.
Atopic diathesis: (i) personal or family history (asthma, allergic rhinitis and/or conjunctivitis, and atopic dermatitis); and/or (ii) 
predisposition to overproduction of immunoglobulin E (IgE) antibodies.
Diagnostic criteria for atopic dermatitis
1. Pruritus
2. Typical morphology and distribution
1) Eczematous dermatitis
- Acute lesions: erythema, exudation, papules, vesiculopapules, scales, crusts
- Chronic lesions: infi ltrated erythema, lichenifi cation, prurigo, scales, crusts
2) Distribution
- Symmetrical
Predilection sites: forehead, periorbital area, perioral area, lips, periauricular area, neck, joint areas of limbs, trunk
- Age-related characteristics
Infantile phase: starts on the scalp and face, often spreads to the trunk and extremities
Childhood phase: neck, the fl exural surfaces of the arms and legs
Adolescent and adult phase: tendency to be severe on the upper half of body (face, neck, anterior chest and back)
3. Chronic or chronically relapsing course (usually coexistence of old and new lesions)
- More than 2 months in infancy
- More than 6 months in childhood, adolescence, and adulthood
Defi nitive diagnosis of atopic dermatitis requires the presence of all three features without any consideration of severity.
Other cases should be evaluated on the basis of the age and clinical course with the tentative diagnosis of acute or chronic, 
non-specifi c eczema.
Differential diagnosis (association may occur)
Contact dermatitis, seborrheic dermatitis, prurigo simplex, scabies, miliaria, ichthyosis, xerotic eczema, hand dermatitis
(non-atopic), cutaneous lymphoma, psoriasis, immune defi ciency diseases, collagen diseases (systemic lupus erythematosus, 
dermatomyositis), Netherton’s syndrome
Diagnostic aids
Family history (bronchial asthma, allergic rhinitis and/or conjunctivitis, atopic dermatitis), personal history (bronchial asthma, 
allergic rhinitis and/or conjunctivitis), follicular papules (goose-skin), elevated serum IgE level
Clinical types (not applicable to the infantile phase)
Flexural surface type, extensor surface type, dry form in childhood, head/face/neck/upper chest/back type, prurigo type, eryth-
roderma type, combinations of various types are common
Signifi cant complications
Ocular complication (cataract and/or retinal detachment): especially in patients with severe facial lesions, Kaposi’s varicelli-
form eruption, molluscum contagiosum, impetigo contagiosa
Adapted from reference 1.
pets and often show positive reactions to multiple al-
lergens. Preventing exposure to the allergens that
have been proven positive is expected to improve or
prevent exacerbation of rashes.
(4) Patch test: A patch test can be applied to aller-
gens acting externally, such as inhalation allergens,
including mites.
(5) Others: Laboratory data reportedly used as a
reference for disease conditions include lactate dehy-
drogenase (LDH), eosinophil cationic protein (ECP),
soluble IL-2R, soluble E-selectin, and thymus and
activation-regulated chemokine (TARC). In particu-
lar, the serum TARC level has been revealed to re-
flect quickly, a short-term disease activity of atopic
dermatitis.13
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Table　2　Severity index
There are several criteria proposed for severity assessment of atopic dermatitis at present that require profi ciency in assess-
ment. Accordingly, the following severity levels are defi ned as indices for treatment.
Mild: Only mild rashes are observed irrespective of the area.
Moderate: Rashes with severe infl ammation are observed in less than 10% of the body surface area.
Severe: Rashes with severe infl ammation are observed in ≥10% to <30% of the body surface area.
Most severe: Rashes with severe infl ammation are observed in ≥30% of the body surface area.
Mild rash: Lesions are seen chiefl y with mild erythema, dry skin, or desquamation.
Rashes with severe infl ammation: Lesion with erythema, papule, erosion, infi ltration, lichenifi cation, etc.
Adapted from reference 15.
3.3. SEVERITY CRITERIA FOR ATOPIC DERMA-
TITIS
(1) SCORAD: SCORAD is an international severity
criterion that has been most popularly adopted in the
English-written literature at present. These criteria
grade the rash areas, severity of rash elements such
as erythema, edemapapule, exudationcrust, licheni-
fication, scratch marks, xerosis cutis, and subjective
symptoms such as itch, and insomnia, by weighting
them at a ratio of approximately 2 : 6 : 2.
(2) Atopic dermatitis severity classification of the
Japanese Dermatological Association: This severity
criteria assesses severity based on the total scores of
3 rash elements (erythemaacute papule, moisten-
ingcrust, chronic papuletuberclelichenification)
and rash areas of the body divided into the following
5 sections: head and neck, anterior body trunk, poste-
rior body trunk, upper limbs, and lower limbs.14
(3) Severity index in this guideline: This guideline
adopts an easy-to-use severity index proposed by the
Health and Labour Sciences Research in the “Guide-
lines for the Treatment of Atopic Dermatitis 2008”15
(Table 2).
4. CLINICAL SYMPTOMS OF ATOPIC DER-
MATITIS
Clinical symptoms: Clinical symptoms of atopic der-
matitis are divided into 3 age groups: infancy
(younger than 2 years old), childhoodschool-age (2-
12 years old), adolescenceadulthood (13 years and
older).
4.1. CUTANEOUS SYMPTOMS
The most important cutaneous symptoms for atopic
dermatitis are rashes and itches.
4.1.1. Rash
There is a report on classification of rashes of atopic
dermatitis from 3 perspectives: age groups, morphol-
ogy and distribution, and sites.
(1) Rash morphology: Atopic dermatitis is a cutane-
ous disease that belongs to eczemadermatitis. Pa-
tients with atopic dermatitis under long-term treat-
ment with a topical steroid develop further diverse
symptoms with such side effects as skin atrophy and
telangiectasia. These symptoms will develop into fur-
ther complicated cutaneous symptoms when an infec-
tious disease occurs concurrently.
(2) Characteristics of rashes by age groups
a) Infancy (younger than 2 years old): A rash usu-
ally develops on the cheek, forehead, or the head,
and causes flushing or papules. It will erode and ex-
ude by being scratched and the exudate will form a
crust when it is dried.
b) Childhoodschool-age (2-12 years old): The skin
is apt to develop an atopic condition by gradually
tending to be dried due to degradation of the sebum-
secretion capacity. In addition, the atopic skin may be
repeatedly scratched to develop prurigo nodularis,
erosions, blood crusts, and so on. Rashes most typi-
cally observed in the childhood to the school-age
group include a bend type.
c) Adolescenceadulthood (13 years and older):
This age group is apt to suffer from seborrhea or
acne due to the increase in sebum secretion with
modified rashes. The rash extends from the neck to
the upper chest region and the upper part of back and
spreads like a clothes hanger. Together with the
rashes on the face and the neck, it is distributed like
a sculptural portrait (portrait type).
(3) Secondary cutaneous changes
a) White dermographism
b) Goosebumps skin
c) Pityriasis alba
d) Pigmentation: This includes postinflammatory
pigmentation, frictional pigmentation, dirty neck, etc.
and is clinically known for orbital darkening and
punctate pigmentation in the lips.
e) Folds: Folds may be seen in from the inner an-
gle to the outer downward of the palpebra inferior
(Dennie-Morgan infraorbital fold), in the neck (ante-
rior neck folds), and in the abdomen. A finding called
palmar hyperlinearity indicates a large number of in-
born palmer folds.
f) Hair loss: Hair loss is seen in the occipital region
for infant patients, in the temporal region for school
age or older patients, and in the eyebrow for adult pa-
tients. Eyebrow hair loss is seen mostly in the outer
half (Hertoghe’s sign).
g) Nail luster: Hard scratching causes pearl-like
Atopic Dermatitis
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luster of nails (pearly nail).
h) Diffuse flushing of the facial surface: The face
may acutely flush over the entire surface. It is likely
caused by sustained inflammation and scratching.
4.1.2. Itch
Itch is caused by increase in skin temperature result-
ing from bathing, exercise, sleep, ointment applica-
tion, etc., sweating due to irritation and body warmth
(itch when sweating), and perspiration stimulation. It
also occurs when woolen clothes contact the skin
(wool intolerance).
(1) Control of itch: In early infancy, the negative
impact of scratching can be weakened by covering
the scratched site with bandages, clothing, etc., or by
wearing gloves. It is not until adolescence that one
understands that scratching will aggravate the cuta-
neous symptoms and comes to restrain oneself from
scratching.
(2) Sleep disorders: Sleep disorders include diffi-
culty in falling asleep and awakening during the
night. The difficulty in falling asleep is caused by a
strong sensitivity to itch due to body warmth while
sleeping.
(3) Scratch addiction: While scratching during the
nighttime is an unconscious reflex movement,
scratching during the daytime involves a conscious
element. It is reportedly a scratching phenomenon
that is performed unintentionally but preferably
(scratch addiction).16
4.2. SYMPTOMS OTHER THAN CUTANEOUS
SYMPTOMS
4.2.1. SymptomsFindings Incidental to Rashes
Dermatopathic lymphadenopathy occurs when a cu-
taneous symptom with certain severity and spread
may cause swelling of regional superficial lymph
nodes. It is indolent and not indicative of infection.
4.2.2. Symptoms in Other Organs
(1) Cataract: Cortical cataract with an anterior sub-
capsular or posterior subcapsular opacity may pro-
gress to cover all layers. With a gender ratio of ap-
proximately 1 : 2, it occurs most frequently in indi-
viduals 15-24 years of age, with a severe form of rash
on the facial surface in particular. The frequencies of
complications with cataracts are reported to be 2.0%
of all patients and 5.5% of severe patients.
(2) Retinal detachment: The retinal detachment ac-
companying atopic dermatitis is reported to occur
with a hiatus caused by continuous external forces
applied to the eyeball. It occurs predominantly be-
tween the ages of 16 to 25 and frequently among pa-
tients who strongly rub their eyelids or who pat their
own faces. The frequencies of complications with reti-
nal detachment are reported to be 0.5% of all patients
and 2% of severe patients.
(3) Airway hyperresponsiveness: A study on airway
hyperresponsiveness caused by histamine inhalation
load in children with atopic dermatitis found that pa-
tients with atopic dermatitis not complicated with
asthma showed significantly worse airway hyperre-
sponsiveness compared with healthy controls.
(4) Mental symptoms: Atopic dermatitis may cause
symptoms such as social withdrawal resulting from
disappointment with existing therapies, discontent
with responses of doctors, disappointment with the
probability of cure, and so on. Severe atopic dermati-
tis cases may be accompanied by psychosomatic
problems.
(5) Neurological symptoms: Paresthesia may occur
in the distal extremities with aggravation of dermati-
tis symptoms and lesional atopic myelitis cervicalis
may be observed in the cervical region in MRI.
(6) Intestinal tract symptoms: Severe cases may be
accompanied by such symptoms as diarrhea and con-
stipation.
5. INVESTIGATION OF CAUSES AND EXAC-
ERBATING FACTORS FOR ATOPIC DER-
MATITIS AND COUNTERMEASURES
Given that causes and exacerbating factors may vary
according to age, individual differences of patients,
environment, and lifestyle, it is important to take
countermeasures in consideration of the conditions of
the individual patients.
5.1. FOODS
Food allergens are investigated by performing de-
tailed history taking, allergen tests and then by com-
bining elimination tests and provocation tests (not
performed for cases accompanied by anaphylaxis) for
suspicious allergens detected to remove the deter-
mined allergens. Countermeasures are taken by nu-
tritional care introducing alternative foods introduced
and providing guidance to the family without ran-
domly removing allergens.
5.2. SWEATING
Sweating is an important cause and exacerbating fac-
tor for atopic dermatitis, hence washing away sweat
by bathing and showering will lead to the improve-
ment of symptoms. Bathing and showering are im-
portant not only for washing away the components of
perspiration but also for washing away allergens,
such as dust and pollens, and microbes on the skin
surface.
5.3. PHYSICAL IRRITATION
Causes and exacerbating factors other than the
above-mentioned perspiration include clothes, dry
air, hairs, and cosmetics for adult patients. Cosmet-
ics, shampoo, and soaps need to be selected appropri-
ately, exchanging products that cause symptoms.
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5.4. ENVIRONMENTAL FACTORS
Allergens such as mites and house dust, pollen aller-
gens in specific seasons, and organic solvents such as
formaldehyde and toluene can become problematic.
Being sensitized to mites in infancy is reportedly a
marker for the development of asthma.17 Periocular
pathological changes are often observed during air-
borne pollen seasons.18
5.5. MICROBESFUNGI
If no infectious symptoms are seen in the affected
part, a topical steroid can be applied to encourage the
improvement of the cutaneous symptom, even if the
site is densely populated with Staphylococcus aureus
(with bacterial counts of 1000 cfu10 cm2 or more as
detected by the stamp method).
(1) An antimicrobial therapy should be performed
if any infectious symptoms are observed.
(2) Care should be taken against microbial substi-
tution with methicillin-resistant Staphylococcus aureus
(MRSA).
(3) The skin should be kept clean by frequent bath-
ing or showering, etc.
(4) Disinfectants such as povidone-iodine solution
should not be applied.
5.6. CONTACT ANTIGEN
Contact dermatitis is divided into allergic contact der-
matitis, which is developed by a sensitized patient,
and primary irritant contact dermatitis, which can be
developed by anyone depending on the antigen level.
A patient with atopic dermatitis is susceptible to both
types of contact dermatitis due to deterioration of the
cutaneous barrier functions and the long-term appli-
cation of external medicines.
5.7. STRESS
Aggravation by mental stress is often experienced in
daily medical practice. The high rate of aggravation of
atopic dermatitis reported in areas affected by the
Great Hanshin-Awaji Earthquake definitely proves
the correlation between stress and atopic dermati-
tis.19
5.8. SCRATCHING
Scratching will not only damage the cutaneous bar-
rier functions by injuring the skin, but also worsen
the symptoms by causing the release of various phlo-
gogenic agents.
5.9. OTHERS
The pathology of atopic dermatitis is a chronic inflam-
mation of the skin that is aggravated by the deteriora-
tion of compliance. It is necessary to educate patients
repeatedly so they may understand the pathology and
realize that a long-term antiinflammatory therapy is
required.
6. SUMMARY OF THE BASIC THERAPY OF
ATOPIC DERMATITIS
6.1. BASICS OF TREATMENT
Because the treatment of atopic dermatitis requires
appropriate diagnosis and evaluation of cutaneous
symptoms, the basics of treatment under this guide-
line include 3 mainstays. These are investigation and
countermeasures of causes and exacerbating factors;
second, correction of skin dysfunctions (skin care);
and third, pharmacotherapy. These are based on the
concept that this disease is an inflammatory cutane-
ous disease that forms an eczematous lesion against a
backdrop of atopic diathesis, with numerous factors
involved in the occurrence and aggravation and aber-
rant function in the skin (Fig. 4). These 3 points are
equally important and thus need to be appropriately
combined in accordance with the symptoms of each
patient.
(1) Investigation and countermeasures of causes
and exacerbating factors: Because the importance of
the individual factors depends on the individual pa-
tients, it is important to investigate fully the factors
through diagnosis, and to take reasonable and appro-
priate countermeasures (see 6-5).
(2) Skin care (correction of abnormal cutaneous
functions): The skin barrier functions of patients with
atopic dermatitis are deteriorated due to abnormality
in function such as deteriorated water retentivity, low-
ered threshold of itch, and susceptibility to infection.
Correcting those abnormalities (skin care) is ex-
tremely important in treatment, chiefly by good hy-
giene and moisture retention of the skin.
(3) Basics of pharmacotherapy: If countermeasures
against the causes and exacerbating factors and the
skin care have not resulted in improvement of derma-
titis, pharmacotherapy will be needed. A topical ster-
oid can be applied to control the inflammation of
atopic dermatitis in principle. A topical tacrolimus can
also be applied as needed. In addition to external
medicines, antihistaminics or antiallergics may be
taken internally to supplement these remedies as
needed, in expectation for an antipruritic effect and a
partial antiinflammatory effect. Steroids should not be
administered internally in principle, but may be ap-
plied temporarily for a short term only to patients
with extremely acute symptoms and the most severe
cases that cannot be controlled by external medicines
only.
6.2. PRECAUTIONS DURING TREATMENT
If an abnormal change is observed in symptoms dur-
ing treatment or if no improvement is observed after
treatment based on a basic therapy for approximately
one month, referral to a more specialized medical in-
stitution should be considered. Hospital treatment is
effective for patients with severe or most severe
cases.
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Fig.　4　Important points of these guidelines. Modifi ed from reference 15.
2. Assessment of cutaneous symptoms
In selecting a therapy, cutaneous symptoms need to be properly assessed.
3. Basics of treatment
Based on the above assessment, investigation/countermeasures against 
causes and exacerbating factors, skin care, and pharmacotherapy should be 
implemented by being optimally combined for each patient. Sufficient 
information about the treatment should be transmitted to the patient to build a 
favorable partnership.
1. Diagnosis
Appropriate diagnosis should be ensured by discriminating them from other 
diseases with similar symptoms, such as eczema and dermatitis, in accordance 
with the abovementioned concept.
Outline of the guidelines for therapy
Pharmacotherapy
Diagnosis
Severity assessment
Investigation/countermeas-
ures against causes and 
exacerbating factors
Skin care 
(correction of abnormal 
cutaneous functions)
7. SKIN CARE AGAINST ATOPIC DERMATI-
TIS
Skin care is highly important, as is shown by consid-
eration of the fact that the skin tends to become more
prone to drying due to aging, and given the adverse
effects of settlement of Staphylococcus aureus on the
skin on the aggravation of symptoms.
7.1. DRY SKIN
The skin of patients with atopic dermatitis is gener-
ally in a dried condition, not only in the lesion but
also in an apparently normal area, due to insensible
water loss (transepidermal water loss; TWL). In such
conditions, with facilitation of transcutaneous inva-
sion of allergens and irritants, likely resulting in aller-
gic reactions and irritability, patients may come to
suffer from itch due to the lowered threshold of itch.
7.2. Staphylococcus Aureus FLORA
If the bacterial count is small (in the case of a bacte-
rial count of 1000 cfu10 cm2 or less by the stamp
method), dry skin symptoms will be improved only
by continuous use of a moisturizer. If the bacterial
count is larger, it is important to take a skin care regi-
men with consideration of the bacterial flora on the
skin surface.
7.3. IMPORTANT POINTS IN SKIN CARE
(1) Skin care against dry skin: Hydrophilic oint-
ments and water absorptive ointment with high mois-
ture retention include urea preparations, heparinoid
preparations, water-soluble collagen preparations, so-
dium lactate preparations, and elastin hydrolysis
preparations.
(2) Skin care against injured skin: An oleaginous
ointment (ointment in a narrow sense) with skin pro-
tective action should be externally applied.
(3) Good hygiene of the skin and skin care: To en-
sure healthy skin, bathing and showering should be
strictly observed with appropriate moisturizer or skin
protectant applied externally as needed.
(4) Practical home skin care
a) Bathing and showering as basic skin care: With
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Fig.　5　Administration method of topical steroid against atopic dermatitis. 
†This medicine should be applied to an inpatient in liaison with specialist doctors. 
Modifi ed from reference 15.
.
the roles of the Staphylococcus aureus flora on the
skin surface gradually revealed, the effects of bathing
and showering are being re-evaluated.20,21 While
washing the skin during bathing and showering is ef-
fective for most patients, it is not recommended that
they strongly scrub down themselves with a towel.
b) Precautions in use of soap and shampoo: Pa-
tients can use an ordinary soap and shampoo. Prod-
ucts with no or minimal aroma and synthetic addi-
tives and with lower surfactant component are prefer-
able.
c) Moisture retention after bathing: it is important
to apply an ointmentcream to the skin to protect the
coating and to retain moisture as soon as possible af-
ter bathing.
8. PHARMACOTHERAPIES FOR ATOPIC
DERMATITIS
8.1. EXTERNAL MEDICINE
8.1.1. Topical Therapy
Topical therapy refers to skin care chiefly with mois-
turizers, and to inflammation control chiefly with topi-
cal steroids and tacrolimus ointments (immunosup-
pressive ointment, topical calcineurin inhibitor). Topi-
cal steroids are external medicines that play a central
role in the treatment of atopic dermatitis. A topical
steroid in the appropriate rank should be applied ac-
cording to the severity and the site of cutaneous
symptoms and the age of the patient. Tacrolimus oint-
ments (protopic ointment 0.1% for 16 years or older;
protopic ointment 0.03% for younger children) should
be applied with attention to the dose and precautions
after obtaining an informed consent from the patient
for the requirements. Tacrolimus ointments are re-
vealed to have an efficacy equivalent to a topical ster-
oid of the strong class. Accordingly, it is important to
combine properly the tacrolimus ointment with the
topical steroid with the objective of alleviating the
side effects of the topical steroid.
8.1.2. PharmacologyAction Mechanism of the
Steroid Drug
Upon entering a cell, steroids bind receptors that
form complexes with heat shock protein (HSP90),
which is found in the cytoplasm, and migrate with the
complex into the nucleus. There they activate steroid-
responsive genes to exert their pharmacological ac-
tions that include antiinflammatory action in a narrow
sense, antiallergic action, and immunosuppressive ac-
tion.22
8.1.3. Administration Method of Topical Steroids
(1) Selection of topical steroid: Topical steroids are
classified into 5 ranks from weak to strongest. A ster-
oid of an appropriate rank should be used in accor-
dance with the severity of cutaneous symptom23 (Fig.
5).
(2) Points to note in external application of steroid:
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Table　3　Side effects of topical steroid in the skin or affected part
1. Acne-like rash, including folliculitis and rosacea
2. Eyelid and perioral dermatitides
3. Epidermal-dermal atrophy, dermal vulnerability (most likely to occur on the geriatric or sunlight damaged skin, intertrigi-
nous zone, or facial surface)
4. Delay in wound healing
5. Gluteal granuloma
6. Purpura
7. Telangiectasia and erythema
8. Skin striae
9. Depigmentation
10. Hypertrichosis
11. Hidden or exacerbated dermatophyte infection
12. Secondary infection or exacerbation of existing infection
13. Contact dermatitis
(i)  May be caused by an ingredient of the preservative or other base material.
(ii) May be caused by a corticosteroid molecule. In this case, the skin may cross-react with a corticosteroid molecule of 
similar structure.
14. Others
Adapted from Drake LA, et al. J Am Acad Dermatol 1996;35:615-9.
Fig.　6　Index of external dose of topical steroid: fi nger tip unit (FTU). 1 FTU is the 
quantity of ointment that will be pushed out of a tube of 5 mm in diameter onto the 
region from the DIP joint to the distal end on the pulp side of an adult’s forefi nger 
and is equivalent to approximately 0.5 g. 1 FTU can cover 2 palms of an adult. 
Adapted from reference 15.
A topical steroid to be applied to atopic dermatitis
must be selected in accordance with the severity and
the site of symptoms and the age of the patient.
a) Application to the facial surface and points to
note: A topical steroid should be applied carefully to
the facial surface, neck, etc., which have an active
percutaneous absorption. When it is applied to such
sites, the administration should be limited to the
shortest period possible in consideration of progres-
sive reduction, intermittent administration, and a
change to tacrolimus ointment as soon as possible.
b) Topical steroids and side effects: Patients should
be evaluated for severity of their condition approxi-
mately 1-2 weeks after the start of treatment with a
topical steroid to identify any side effects and the
need for stepping down or stepping up the dose. The
absorption ratio of steroids varies significantly among
skin sites. In children and the elderly with deterio-
rated cutaneous barrier functions and in summer
when there is a higher sweat volume, the absorption
ratio changes. Well-known side effects of steroid di-
rectly affecting the skin are shown in Table 3. If side
effects are seen during treatment with topical ster-
oids, the therapy should be shifted to a tacrolimus
ointment while gradually stepping down the dose.
c) Monitoring of the dose of topical steroid: Moni-
toring should be performed twice daily (morning,
evening, and after bathing). Improvement in symp-
toms should be evaluated with the goal of gradual
progressive reduction to change the therapy to a topi-
cal nonsteroidal agent, while ensuring the absence of
relapse after once a day to alternate-day administra-
tion. The finger-tip unit (FTU) will be used as an in-
dex of external dose.24 One FTU is a quantity of oint-
ment that will be pushed out of a tube of 5 mm in di-
ameter onto the distal end on the pulp side of an
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adult’s forefinger and is equivalent to approximately
0.5 g. One FTU can cover two palms of an adult (2% of
the body surface area) (Fig. 6). The dose required to
cover the whole body is 50 FTU or 25 g. A dose for
children is also proposed.25
It has been reported that a topical steroid of the
strong class or higher shows no difference in efficacy
after 3 weeks or more between twice-a-day external
application and once-a-day external application. It is
recommended that a strong topical steroid be initially
applied twice a day and then changed to once-a-day
application after remission of an acute or intractable
lesion is observed, for the purpose of enhancing the
compliance of the patient, reducing side effects, and
reducing medical expenses.26
d) Response to exacerbation due to discontinuation
of long-term application of a topical steroid: Patient
should be advised against discontinuing the use of
the drug on his own judgment. In addition, sufficient
explanation should be provided to the patient about
the side effects likely to be caused by the topical ster-
oid and that the side effects can be avoided by evalu-
ating cutaneous symptoms and monitoring drug con-
sumption.27
e) Measures against acute exacerbation: In the
event of acute exacerbation of a cutaneous symptom
due to a change of treatment on the patient’s own
judgment etc., a topical steroid should be adminis-
tered at a necessary and sufficient dose. If systemic
aggravation is observed, the patient should be hospi-
talized for a short period and a steroid systemically
administered as needed. If an infectious disease is
suspected, an antimicrobial or an antiviral should be
administered as needed under the guidance of a spe-
cialist. Ocular complications such as retinal detach-
ment and cataract are mostly observed when the dis-
ease is aggravated due to irregular use or discontinu-
ation of a topical steroid. The patient should be in-
spected for ocular conditions including visual acuity
on a routine basis through history taking etc., and
should undergo physical examinations by an ophthal-
mologist as needed.
f) Precautions in external application of steroid in
children: It should be emphasized in children as well
that antiinflammatory therapy plays a central role in
pharmacotherapy chiefly with a topical steroid. Ad-
ministration methods for children are divided into the
age groups of <2 years of age, 2-12 years of age, and
>13 years of age, as shown in Figure 5. Care should
be taken so that insufficient administration for fear of
side effects likely generated in the treatment of chil-
dren may not result in prolonged symptoms.
(3) Selection of external medicine according to
symptoms: In principle, in the treatment of atopic der-
matitis, a moisturizer or skin care product should be
applied to a mild eczematous lesion or dry skin on
the facial surface without applying any topical ster-
oids. It is reported that twice-a-day external applica-
tion of a moisturizer (preparation containing hepari-
noid) significantly inhibits the relapse of inflamma-
tion of atopic dermatitis compared with the untreated
group (no application group).
8.1.4. Steroid Unresponsiveness and Tachyphy-
laxis
The guidelines of care for atopic dermatitis of the
American Academy of Dermatology states “there are
no studies or theses that support the alleged indica-
tion that topical steroids may cause tachyphylaxis.28”
Reasons for attenuating effects need to be considered
over several factors including the rank of steroid
used, administration method (compliance), and exac-
erbating factors.
8.1.5. Administration Method for Topical Im-
munosuppressant
Tacrolimus ointments (trade name: protopic oint-
ment) are available in 2 dose forms: ointment 0.1% ap-
plicable to patients 16 years of age or older and oint-
ment 0.03% applicable for children aged 2-15 years.
Tacrolimus ointments should be applied to sites
where a topical steroid is apt to develop side effects,
such as the facial surface, and to lesions where the
topical steroid shows no effects. The agent should be
externally applied once a day after bathing, up to a
maximum of twice a day. Although it is reported that
continuous external application of tacrolimus oint-
ment 2-3 times a week will significantly inhibit the re-
lapse of symptoms (proactive therapy),29 the therapy
needs to be evaluated in Japanese patients in consid-
eration of such issues as administration period, dose,
applicable sites, and safety in long-term use. This can-
not be applied for safety reasons to patients with
nephropathy, pregnant patients, patients with ich-
thyosiform erythroderma (Netherton syndrome,
etc.), infants aged less than 2 years, and patients un-
der phototherapy. Tacrolimus ointment must be used
after obtaining an informed consent from the patient
for several precautions set forth by the seller for the
use.30
8.1.6. Topical Non-Steroidal Antiinflammatory
Drugs
No data definitely shows that nonsteroidal antiinflam-
matory drugs (NSAIDs) are effective for eczematous
lesions of atopic dermatitis. There is no description of
NSAIDs in the guidelines for the treatment of atopic
dermatitis of the United States or Europe. There are
reports of cases where children administered an topi-
cal antiinflammatory drug developed contact dermati-
tis.
Note: Although it is common that a topical steroid
is used in combination with another external medi-
cine, it is suggested that the individual agents be
used separately, given the disparity between the dilu-
tion effect obtained from the mixture and the vaso-
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constrictive capacity, and given the deterioration of
efficacy by a moisturizer with an alkaline base.
8.2. INTERNAL MEDICINE
8.2.1. AntihistaminicsAntiallergics
(1) Pharmacological actionsaction mechanism:
First-generation antihistaminics, second-generation
antihistaminics, and antiallergics with indication for
atopic dermatitis are applied.
a) Antihistaminics: The major pharmacological ac-
tion of antihistaminics is to antagonize histamine in
the histamine H1 receptor of the tissue to inhibit the
action. Histamine binds to the histamine H1 receptor
in cutaneous capillaries and on the membranes of pe-
ripheral nerves to cause hyperpermeability of plasma
components from capillaries, vascular dilation, itch,
etc.
b) Antiallergics: Antiallergics are divided into me-
diator antireleasers, which are antiallergics in a nar-
row sense, thromboxane A2 inhibitors, leukotriene
receptor antagonists, cytokine inhibitors, as well as
classic antihistaminics. Antiallergics inhibit the re-
lease of the preformed mediators from mast cells in
Type I allergic reactions, inhibit the generation and
release of newly-formed mediators, and antagonize
against mediators bound to receptors. Disodium cro-
moglycate may be applied only to atopic dermatitis
with food allergy. Suplatast tosilate inhibits the accu-
mulation of eosinophils to inflammatory sites by in-
hibiting the production of Th2 cytokines.
(2) Administration method: Since differences in ef-
ficacy are found amongst individual patients in daily
medical care, it is necessary to explore and replace
drugs that are not effective after 2 weeks of admini-
stration with another drug appropriate for the individ-
ual patient.
a) Treatment of itch: Since itch is normally caused
by irritation of the end of C nerve fiber located at the
epidermal-dermal junction. The histamine H1 recep-
tor is located at the C fiber, and antihistaminics and
antiallergics with antihistaminic action are expected
to inhibit itch.
b) Evidence of efficacy of antihistaminics: Antihis-
taminics and antiallergics are considered effective
only against peripheral itch.
c) Comparison between antihistaminics and antial-
lergics (consensus among guidelines):
(i) Antiallergics show pharmacological actions not
covered by conventional antihistaminics, such as his-
tamine release inhibitory action and eosinophilic che-
motaxis inhibitory action.
(ii) Most antiallergics have stronger antihistaminic
action than conventional antihistaminics.
(iii) Antiallergics are generally easier to use be-
cause they have no anticholinergic action or central
inhibition.
(iv) The cost of antiallergics is higher.
(v) Administration of antihistaminics in the evening
enables its central inhibitory action, which is good for
comfortable sleep and inhibition of scratching at
night.
(3) Side effects
a) Central nervous system effect: The drug gener-
ally generates side effects in the form of sleepiness,
loss of concentration, or malaise, and it may cause ex-
citement if administered in a large quantity. Precau-
tion is necessary in use of antihistaminics in children,
particularly against convulsion. A second-generation
antihistaminics is characterized by reduced sleepi-
ness and central nervous system effects because it
has more difficulty in passing through the blood-
brain barrier. In evaluating sedation, sleepiness
should be differentiated from impaired performance
(a condition with deteriorated operating efficiency).31
b) Anticholinergic action: The anticholinergic ac-
tion may cause dry mouth, sense of mucosal dryness,
urinary retention, and so on. This drug is contraindi-
cated for patients with glaucoma or lower urinary
tract obstructive disease (prostatomegaly, etc.).
c) Digestive symptoms: These include nausea,
vomiting, diarrhea, and abdominal pain.
d) Teratogenicity: An antihistaminics generally
passes through the placenta and through the blood-
brain barrier of the fetus. Antihistaminics known to
be safe to pregnant women are chlorpheniramine and
clemastine, and these are first-line drugs for pregnant
patients. Most antiallergics are relatively new and
thus their safety for pregnant women is not well
known. Accordingly, the aforementioned antihista-
minics should be selected as needed.
e) Application to patients with hepatic dysfunction:
Antiallergics are mostly metabolized in the liver and
excreted into the urine. However, the frequency of
the occurrence of drug induced hepatopathy due to
antiallergics is low.
f) Application to patients with renal dysfunction:
For drugs excreted through the kidney as the main
excretion pathway (ketotifen fumarate, cetirizine hy-
drochloride, epinastine hydrochloride, oxatomide, be-
potastine besilate, tranilast, etc.), decreased renal
function may inhibit the excretion of the drug, result-
ing in a rise in blood levels of that drug. In that case,
use of drugs that are decomposed chiefly in the liver
(azelastine hydrochloride, ebastine, emedastine difu-
marate, etc.) or excreted into feces (fexofenadine hy-
drochloride) is recommended.
g) Drug interactions: A general drug interaction of
an antihistaminics is caused by concomitant use with
other central depressants. Concomitant use of the
drug with alcohol, hypnotic, or psychotropic drugs
and so on, may cause massive sedation, vertigo, mal-
aise, weakness etc. Concomitant use with tricyclic an-
tidepressants or anticholinergics may cause dry
mouth, intestinal obstruction, aggravated glaucoma,
memory disorder, etc. Concomitant use with a
monoamine oxidase (MAO) inhibitor may cause
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headache, arrhythmia, hypertension, etc. because of
the strengthened action of catecholamine. Few antial-
lergics have similar interactions as are seen in anti-
histaminics.
8.2.2. Other Internal Medicines
(1) Steroid internal medicine: Because the internal
application of a steroid has various severe side ef-
fects, long-term administration of the agent should be
avoided. In general, prednisolone should be adminis-
tered to an adult patient at a dose of 10-15 mgday in
combination with antihistaminics or antiallergics and
discontinued within as few days as possible. The use
of these drugs in children with atopic dermatitis is
not recommended in consideration of the side effects.
(2) Immunosuppressant: Cyclosporine (NeoralⓇ)
was added to the list of treatments of atopic dermati-
tis in October 2008, in Japan. Cyclosporine is newly
applicable to patients aged 16 years or older with re-
sistance to existing therapies, subject to a washout
within 3 months of administration, as required by the
administration guidelines. The drug will be usually
administered twice a day at a daily dose of 3-5 mg
kgday. The patients need to be periodically in-
spected for several side effects, similar to cases of
psoriasis vulgaris.1,32
9. ADJUNCTIVE THERAPIES OTHER THAN
THE BASIC THERAPY OF ATOPIC DERMA-
TITIS
This section introduces adjunctive therapies other
than the basic therapy with relatively firm evidence.
9.1. ULTRAVIOLET LIGHT THERAPY
Narrowband UVB (NB-UVB) is an ultraviolet light
consisting of narrow wavelengths of 311 nm at peak
that have safer and higher therapeutic effects since it
does not contain the ultraviolet light of 300 nm or
smaller that have strong phototoxicity. In the treat-
ment of atopic dermatitis, the irradiation level is usu-
ally reduced from the level applied to psoriasis with
initial irradiation at 50%MED and dose increases by
0.1 Jcm2. While no cases of oncogenesis have been
reported, the possibility of oncogenesis has not been
conclusively ruled out. UVA1 enables a large amount
of irradiation without causing an erythemic reaction
and is effective for severe cases and acute exacerba-
tion when applied in treatment. While it is revealed to
be effective both at a high dose (130 Jcm2) and at a
medium dose (50 Jcm2), application of the therapy is
prohibited for patients aged under 18 and for mainte-
nance therapy in consideration of oncogenic risk.
9.2. HERBAL MEDICINES
Those herbal medicines covered by the health insur-
ance system and medicines with safety proven in con-
trolled studies, such as Hochuekkito are used.
Jumihaidokuto, Shofusan, Saikoseikanto, and Ho-
chuekkito are Chinese medicine prescriptions that
contain a licorice that may cause pseudoaldostero-
nism or myopathy. Hochuekkito is reported to cause
interstitial pneumonitis, hepatic dysfunction, and
jaundice and thus requires due caution in use.
9.3. n-3 POLYUNSATURATED FATTY ACID
This therapy should be applied when a rise in the n-
6n-3 ratio is observed in measurements of blood un-
saturated fatty acid levels. Adoption of this therapy
should be consideration when both poor intake of the
n-3 polyunsaturated fatty acids and excessive intake
of n-6 polyunsaturated fatty acids are confirmed with
a rise in the n-6n-3 ratio observed in a review of the
menu of meals (food diary) conducted together with
a nutritionist.
9.4. PSYCHOSOMATIC APPROACH
Counseling will be given by the attending physician
or, as appropriate, by a psychosomatic physician, psy-
chiatrist, or psychotherapist. For general physicians
not specialized in psychosomatic medicine, treatment
by antianxiety agents, antidepressant, or hypnotic is
recommended instead of a psychotropic agent for
pharmacotherapy.
9.5. ALTERNATIVE THERAPY
Many reports are published on the efficacy of acu-
puncture and moxibustion in journals of Eastern
medicine. Balneotherapy, aromatherapy, herb ther-
apy are also reported to be effective. However, since
many of them lack scientific verification and such
therapies may cause aggravation of cases, they
should be performed under the supervision of a phy-
sician. Probiotics are evaluated as having prophylac-
tic effects when administered to the mother and child
and reportedly expected to improve rashes with
slight adjunctive therapeutic effects to children.
In addition to the therapies described above, wide
varieties of folk medicines are used. However, the
number of folk medicines that have been scientifi-
cally verified for efficacy is extremely small. In addi-
tion, cases have been reported where inappropriate
folk medicines deteriorated rashes to develop into
complications such as Kaposi varicelliform eruption,
electrolyte imbalances, hypoproteinemia, poor weight
gain, and growth disturbance. Thus, where patients
are confronted with danger to their lives, guidance
should be given so that they may not easily fall into
an ineffective folk medicine.
10. PRECAUTIONS IN THE PROGRESSION
OF ATOPIC DERMATITIS
10.1. COMPLICATIONS AND COUNTERMEA-
SURES
(1) Allergic diseases: Allergic diseases such as
asthma and allergic rhinitisconjunctivitis are the
most frequent complications. Care should be given in
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prescribing a therapeutic drug for atopic dermatitis,
so that ingredients may not be duplicated with those
in the therapeutic drug for the complication.
(2) Cutaneous infectious diseases: The causative
microorganisms for impetigo contagiosa are Staphylo-
coccus aureus and Streptococcus hemolyticus. Lesions
should be kept clean by regular showering and then
covered with clean gauze so that it cannot be
scratched. Topical antimicrobials should be applied
to the lesion and drugs such as zinc oxide ointment
can be applied to the wet surface. For expanding
rashes, antimicrobials should be administered to the
whole body. Kaposi varicelliform eruption indicates a
condition with a wide area of the body being percuta-
neously infected with herpes simplex virus. The sites
frequently infected by the disease are the facial sur-
face and the neck. For treatment, an antiherpesvirus
agent will be systemically administered. In the case
of a rash in the area surrounding the eye, consult an
ophthalmologist in consideration of probable compli-
cation with herpes corneae.
(3) Ophthalmological diseases: Potential ophthal-
mological diseases include cataract, retinal detach-
ment, blepharitis, keratoconjunctivitis, and kerato-
conus. It is important to treat rashes in the eye area
and allergic keratoconjunctivitis appropriately since
infancy or childhood in liaison with an ophthalmolo-
gist.
10.2. OTHER PRECAUTIONS
Hospital treatment should be considered for patients
with the most severe cases in the severity index. Hos-
pital treatment should be considered for patients with
moderate or severe cases as well. This 2010 Guide-
line describes the internal application of steroids for
the most severe case as a measure “to be taken tem-
porarily as needed.” However, affected children, par-
ticularly those cases complicated with asthma, re-
quire a close liaison with a specialist since discontinu-
ation of the internal application of steroids may aggra-
vate the symptoms.
11. POINTS IN REFERRAL TO A SPECIAL-
IST
(1) Poor control of cutaneous symptoms: If the
rash does not recover after one month’s treatment, in
accordance with the “Guidelines for the Management
of Atopic Dermatitis 2009,” referral of the patient to a
specialist (specialist in cutaneous allergy, specialist in
childhood allergy, etc.) or special institution should
be considered.
(2) Guidance is needed chiefly in view of the life
environment of the patient: The patient should be ad-
vised to refrain from eating stimulating or spicy foods
that induce itch, meals likely to induce urticaria, to
avoid underwear or clothes with physical irritation, to
keep the skin clean so that it may not develop a sec-
ondary infection by being scratched, and to improve
psychogenic factors such as stress.
(3) More detailed guidance is needed on skin care:
Detailed guidance should be given in accordance
with the patients skin conditions, such as season-
specific bathing and the use of external medicine for
moisture retention.
(4) Diagnosis and guidance of food allergy are
needed: If the external medicine treatment is ineffec-
tive for cutaneous symptoms of infants or children in
particular, and there is evidence of the involvement of
food allergens, the patient should be tested for food
allergies to provide dietary instructions.
(5) Extraneous factors for scratch addiction needs
to be analyzed and corrected: A patient with scratch
addiction needs to be encouraged to be very con-
scious that scratching is the primary factor for the in-
tractability of hisher dermatitis. There are cases
where the condition is improved by guidance.
(6) A folk medicine needs to be coped with: Folk
medicines do not need to be stopped if the patient
and his family willingly use it and are satisfied with it.
However, cases with obviously aggravation or have
side effects need to stop using these to the maximum
extent possible.
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